



HAL
open science

Criteria to define response to therapy in paediatric rheumatic diseases

Nicolino Ruperto, Angela Pistorio, Angelo Ravelli, Rachana Hasija, Dinara Guseinova, Giovanni Filocamo, Erkan Demirkaya, Clara Malattia, Alberto Martini

► **To cite this version:**

Nicolino Ruperto, Angela Pistorio, Angelo Ravelli, Rachana Hasija, Dinara Guseinova, et al.. Criteria to define response to therapy in paediatric rheumatic diseases. *European Journal of Clinical Pharmacology*, 2010, pp.125-131. 10.1007/s00228-010-0937-8 . hal-00642941

HAL Id: hal-00642941

<https://hal.science/hal-00642941>

Submitted on 20 Nov 2011

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

CRITERIA TO DEFINE RESPONSE TO THERAPY IN THE PEDIATRIC RHEUMATIC DISEASES

¹Nicolino Ruperto, MD, MPH, ²Angela Pistorio, MD, PhD, ³Angelo Ravelli, MD, ¹Rachana Hasija, MD, ¹Dinara Guseinova, MD, ¹Giovanni Filocamo, MD, ¹Erkan Demirkaya, MD, ¹Clara Malattia, MD, ²Alberto Martini, MD, Prof. for the Paediatric Rheumatology International Trials Organisation (PRINTO)

¹Nicolino Ruperto, MD, MPH, Rachana Hasija, MD, Dinara Guseinova, MD, ¹Erkan Demirkaya, MD, ¹Clara Malattia, MD, IRCCS G Gaslini, Pediatria II, Reumatologia, PRINTO, Genova, Italy
²Angela Pistorio, MD, PhD, IRCCS G Gaslini, Servizio di Epidemiologia e Biostatistica, Genova, Italy
³Angelo Ravelli, MD, Alberto Martini, MD, Prof. IRCCS G. Gaslini, Pediatria II, Reumatologia and Dipartimento di Pediatria, Università degli Studi, Genova, Italy

NOTHING TO DISCLOSE FOR ANY OF THE AUTHORS

Please address correspondence and reprint requests to:
Nicolino Ruperto, M.D., M.P.H.
Pædiatric Rheumatology International Trials Organisation (PRINTO)
IRCCS G. Gaslini, Università di Genova
Pediatria II - Reumatologia
EULAR Centre of Excellence in Rheumatology 2008-2013
Largo Gaslini, 5
16147 Genova ITALY
Tel: +39-010-38-28-54 or +39-010-39-34-25
Fax: +39-010-39-33-24 or +39-010-39-36-19
E-mail: nicolaruperto@ospedale-gaslini.ge.it
<http://www.printo.it> or www.pediatric-rheumatology.printo.it

Version of July 5, 2010

ABSTRACT

Purpose. In this review we describe the general methodology and the results of the international projects, conducted by the Paediatric Rheumatology International Trials Organisation (PRINTO), in collaboration with the Pediatric Rheumatology Collaborative Study Group (PRCSG) that were aimed to identify, and validate and criteria for the evaluation of response to therapy in clinical trials and in daily clinical practice in patients with the 3 major paediatric rheumatic diseases (PRD): juvenile idiopathic arthritis (JIA), juvenile dermatomyositis (JDM) and juvenile systemic lupus erythematosus (JSLE).

Methods. The methodological approach to identify and validate outcome measures can be divided into 3 main phases: 1) the development of a preliminary core set of measure to evaluate the outcome (e.g. response to therapy, remission criteria, disease activity or damage etc) through literature review and consensus techniques; 2) a large scale data collection for a prospectively evidence-based validation of the preliminary findings; 3) the final development of a validated criteria for the evaluation of the outcome.

Results. The core sets for 3 diseases included domains that are common to all diseases (physician's global assessment of disease activity; parent's global assessment of the overall patient's well-being; disability and/or health-related quality of life) plus additional domains that are specific for each disease. In order to be classified as responder to a given treatment, a patient should demonstrate different minimum level of improvement ($\geq 30\%$ in JIA, $\geq 20\%$ in JDM and $\geq 50\%$ in JSLE) with no more than 1 of the remaining worsening by more than 30%.

Conclusions. The proposed core sets and definitions of improvement incorporate clinically meaningful change in a composite endpoint for the evaluation of global response to therapy in the major PRD. The definitions are proposed for use in PRD clinical trials, and may help physicians to decide if a child has responded adequately to therapy.

Response to therapy in pediatric rheumatology. Part of TEDDY Supplement

Ruperto et al

Key Indexing Terms: juvenile idiopathic arthritis, juvenile dermatomyositis, and juvenile systemic lupus erythematosus, response to therapy, clinical trials

Short running title: Response to therapy in paediatric rheumatology

For Peer Review

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

INTRODUCTION

Performing clinical trials in paediatric rheumatic diseases (PRD) is made difficult by the small number of eligible patients, the heterogeneity of disease manifestations, and the lack of standardized criteria to assess clinical response. These situation has improved over the last 10 years thanks to several factors: the implementation of adequate US and Europe pediatric legislation [1-4], the existence of two large not-for-profit networks which facilitated successful trial completion, named Pediatric Rheumatology Trials Organsition (PRINTO at www.printo.it or www.pediatric-rheumatology.printo.it) [5] and the Pediatric Rheumatology Collaborative Study Group (PRCSG at www.prcsg.org), the availability of standardized and validated criteria for the evaluation of response to therapy in for the PRD.

Indeed the availability of standardized criteria would provide a common basis for comparing different treatment options, permit study and statistical comparison of patients with different disease manifestations, and facilitate comparisons of different clinical trials with meta-analysis.

The purpose of this paper is to review the general methodology and present the criteria used to define response to therapy in the 3 major PRD: juvenile idiopathic arthritis (JIA), juvenile systemic lupus erythematosus (JSLE) and juvenile dermatomyositis (JDM).

Methodological aspects

One of the specific problem for the PRD is the lack of objective measures that can be reliably used to evaluate response to therapy. Hence the need to use some surrogate clinical and laboratory markers to assess the disease activity level.

In general the methodological approach to solve such problem can be divided into 3 main phases: 1) the development of a preliminary core set of measure to evaluate the outcome under consideration (e.g. response to therapy, remission criteria, disease activity or damage etc) through literature review and consensus techniques; 2) a large scale data collection for a prospectively evidence-based

1
2
3 validation of the preliminary findings; 3) the final development of a validated criteria for the
4
5 evaluation of the outcome under consideration.
6
7
8

9 10 **Consensus methodologies**

11
12 The use of well recognized consensus formation methodologies specifically designed to combine
13
14 judgments from a group of experts in a particular field is considered necessary whenever there are
15
16 no objective measure to properly assess the outcome. The 2 major recognised techniques are the
17
18 Delphi Technique and Nominal Group Technique [6-8]. In brief, the Delphi Technique utilizes a
19
20 series of well defined questionnaire based-surveys while Nominal Group Technique is a structured
21
22 face-to-face meeting designed to facilitate reaching consensus on the topic of study. Consensus
23
24 formation techniques require that each step is based on the results of the previous steps. These
25
26 techniques have been used to develop the outcome measures of several chronic rheumatic diseases,
27
28 including JIA [9, 10], adult rheumatoid arthritis [11], adult-onset SLE [12, 13], and idiopathic
29
30 inflammatory myopathies [14-16] as well as JSLE [17-19] and JDM [20].
31
32
33
34
35
36
37

38 **What is a core set of measures and why it is needed (e.g. in pediatric rheumatology)**

39
40 The core set has to be intended as a minimum list of domains/variables to cover all (or most)
41
42 aspects of the disease and also as a minimum list to be always reported in future studies. Since in
43
44 pediatric rheumatology we lack true outcome measures (e.g. death, pneumonitis, glucose etc), there
45
46 is a need of surrogate markers for the evaluation of the outcome under consideration (in the
47
48 following paragraph briefly referred as outcome) from different perspectives.
49
50
51
52
53

54 **Phase 1. The preliminary core set selection**

55
56 In this initial phase, after a carefully literature review, it is essential to prepare a mailing of people
57
58 potentially interested to participate to sequential questionnaire-based e-mail surveys using the
59
60 Delphi Technique. The mailing list can contains up to several hundreds of people [17] and

Response to therapy in pediatric rheumatology. Part of TEDDY Supplement

Ruperto et al

1
2
3 constitutes the proper denominator against which evaluate the success of the survey that usually
4
5 require a response rate equal to 70-80%. The first questionnaire is generic and is used to evaluate, in
6
7 broad term, which are the variables used in routine clinical practice to assess the outcome. The data
8
9 from the first survey are then analysed and collated to prepare the second one in which the content
10
11 is more specific. In this second survey responders can be asked to concentrate only on the variables
12
13 selected by a minimum threshold of people in the first survey, to select the most important variable
14
15 (e.g. usually no more than 10) and rank them in order of importance. Other surveys if necessary can
16
17 be added.
18
19

20
21 Usually the results of the mailing survey are not sufficient to select the final list of variables to be
22
23 used. In this case the results of the survey, along with a proper literature search can be used to
24
25 convene a nominal group technique consensus conference, among a restricted number of people
26
27 whose goal is indeed to reach the consensus (80% required) on the measures to be included in the
28
29 preliminary core set. Usually the number of person per table (max 2-3 tables) should not be greater
30
31 than 10.
32
33
34
35
36
37

38 **Phase 2. The prospective validation of the preliminary core set(s)**

39
40 The second phase is aimed to formally validate the preliminary consensus based core sets through a
41
42 prospective, large-scale data collection among the members. The objective of this phase is to further
43
44 define and validate the preliminary core set variables to document the outcome. A detailed protocol,
45
46 listing the proper inclusion/exclusion criteria, needs to be set up in order to collect data ideally in a
47
48 prospective fashion. Data collection should try to mimic what is usually done in a clinical trial, with
49
50 a baseline assessment at the time of the starting treatment, and a final assessment after a certain
51
52 follow-up period. Data collection should include all variables in the preliminary consensus based
53
54 core set, plus all additional variables that are deemed necessary in the analysis phase such as
55
56 demographic, clinical and laboratory data, treatment options etc. Following the OMERACT filter
57
58 for outcome measures in rheumatology [21, 22] the main purposes of the validation phase are to
59
60

1
2 evaluate the following properties [17]: feasibility (brevity, simplicity, easy scoring etc); face and
3
4 content validity (variables easiest to use and most credible); responsiveness (ability of each variable
5
6 to detect clinically important change between baseline and 6 months) measured through the
7
8 standardized response mean (SRM) [23]; discriminative ability (ability to discriminate patients who
9
10 improved from those who did not); convergent construct validity to examine whether the construct
11
12 in question is related to other measures in a manner consistent with a priori prediction; collinearity
13
14 (or redundancy); internal consistency by Cronbach's coefficient alpha [24]; finally, the association
15
16 between the core measures and response to therapy as judged by the attending physician can be
17
18 evaluated through a multivariate logistic regression analysis.
19
20
21
22
23
24
25

26 **Phase 3. The definition of improvement**

27
28 At the end of the data collection process the related analysis should be presented to a panel of expert
29
30 (or experienced clinicians) knowledgeable about the outcome, in another nominal group technique
31
32 consensus based meeting. The purposes of the meeting is to discuss the statistical properties of the
33
34 measures and confirm/refine the final core set of measures. Another important goal is to establish
35
36 the amount of change over time, for the variables included in the core set, in order to properly
37
38 quantify the outcome under consideration (e.g. criteria for response to therapy). The meeting should
39
40 therefore properly define the final core set of endpoints, using a combination of statistical criteria
41
42 and consensus formation techniques.
43
44
45
46
47
48
49

50 **THE EXAMPLES IN PAEDIATRIC RHEUMATOLOGY.**

51 52 53 54 **The core sets of measure for JIA, JSLE and JDM.**

55
56 In table 1 are reported the domains and the suggested variable to measures each domain for JIA [9,
57
58 10], JSLE [17-19] and JDM [20]. Variables suggested include the measures which at the present
59
60

Response to therapy in pediatric rheumatology. Part of TEDDY Supplement

Ruperto et al

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

time have the better statistical properties; however in the future other measures appearing in the literature might replace the existing ones if they will demonstrate better statistical properties.

The domains are divided in the common domains (to be used for all 3 diseases) and specific domains.

The common domains for JIA, JSLE and JDM include 2 global assessment, by the physician and by the parents/patients, usually measured with a 10 cm visual analogue scale (VAS) or a 21 circle VAS [25]. Additionally a measure of functional ability (disability) through the Childhood Health Assessment Questionnaire (CHAQ) [26-28] or the Juvenile Arthritis Functionality Scale (JAFS) [29] and/or a quality of life measures is also considered usually through the Physical Summary score (PhS) of the Child Health Questionnaire (CHQ) [28, 30] or the Pediatric Rheumatology Quality of Life Scale (PRQL) [31].

Disease specific domains for JIA includes 2 measures of joint involvement (the number of joints with active arthritis and the number of joints with limited range of motion) [32-35] and an index of inflammation. For systemic JIA children, absence of spiking fever (< 2 days of maximal body temperature $\leq 38^{\circ}\text{C}$ during the week preceding the evaluation) is an additional requirement.

The JSLE specific domains include a global disease activity assessment, either by the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) [36] or the Systemic Lupus Activity Measures (SLAM) [37] or the European Consensus Lupus Activity Measurement (ECLAM) [38, 39] and a measure of kidney involvement (24-hour proteinuria).

Disease specific domains for JDM include a measure of muscle strength as assessed by the Childhood Myositis Assessment Scale (CMAS) [40-42] or the Manual Muscle Testing (MMT) [43]; a global disease activity assessment through the Disease Activity Score (DAS) [44] or alternatively the Myositis Disease Activity Assessment (MDAA, an instrument [45] that combines two partially overlapping tools named the Myositis Disease Activity Assessment Visual Analogue Scale (MYOACT) and the Myositis Intention to Treat Activity Index A-E version (MITAX) [45].

1
2 Overall the measures include in the 3 core sets were found to be feasible and not redundant, to have
3
4 good construct validity, discriminative ability, internal consistency, were responsiveness to
5
6 clinically important change in disease activity, and were associated strongly with treatment outcome
7
8 [9, 10, 17-20].
9
10

11 12 13 14 **The definition of improvement for JIA, JSLE and JDM.**

15
16 In table 2 are reported the definitions of improvement to be used as main outcome in trials JIA [9,
17
18 10], JSLE [17-19] and JDM [20]. The definitions require a minimum level of improvement (30% in
19
20 JIA, 50% in JSLE and 20% in JDM) in x number of the variables included in the core sets (Table 1)
21
22 with no more than one of the remaining variables worsened by more than 30%. For example the JIA
23
24 definition of improvement for JIA is: at least 30% improvement from baseline in 3 of any 6
25
26 variables in the core set with no more than one of the remaining variables worsening by more than
27
28 30%. For trials in systemic JIA absence of spiking fever (< 2 days of maximal body temperature \leq
29
30 38°C during the week preceding the evaluation) is also required. The minimum level of
31
32 improvement has to be reported in all trials as primary outcome but researchers should also report
33
34 more stringent definition of improvement (50, 70, 90 or 100%) as secondary outcome in the trial
35
36 results.
37
38
39
40
41
42
43
44

45 **The definition of flare for JIA**

46
47 An innovative trial design in JIA is the use of the so-called randomized, double-blind controlled,
48
49 withdrawal design. This study design was proposed by Giannini and Lovell for use in pediatric
50
51 rheumatology studies [46] with the rational to avoid the placebo arm for children with chronic
52
53 conditions when alternative effective treatments are available. Eligible children are treated in an
54
55 open label fashion with the experimental therapy to be tested in the trial for a few months after
56
57 which responders (typically those demonstrating an ACR pediatric 30 response) are randomized in
58
59 a double-blind fashion either to continue the experimental therapy or to switch to placebo. In this
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

segment of the study, called the double- blind withdrawal phase, patients who demonstrate a pre-defined definition of disease worsening (e.g. “flare”) are withdrawn from the double-blind withdrawal phase of the trial and re-treated with the experimental therapy in an open label fashion. A peculiarity of this trial design is therefore the need to have a proper definition of flare to be used in the double- blind withdrawal phase. The flare definition currently used in JIA is essentially the inverse of the ACR Pediatric 30 criteria for response [47]. This definition requires that there be at least a 30% worsening in three of the six JIA core set parameters, with no more than one improving by more than 30%. In addition, there are some contingencies requiring that, if either the number of active joints or the number of joints with limitation of motion are used in the flare definition, there must be at least a two joint increase in the number of active joints or those with limited range of motion, respectively. Also, if the physical or parent global scales are used in the flare definition, worsening ≥ 2 cm (on a 0-10 cm scale) is required. Additionally, for systemic JIA patients only, reappearance of spiking fever ($> 38^{\circ}\text{C}$, lasting for at least 2 days in the week preceding the evaluation) not due to infections would signify that a flare have occurred. These flares criteria have been validated and shown to be sensitive, in terms of limiting the degree of the worsening patient symptoms to avoid potential damage in subjects randomized to placebo and those children losing response to the experimental agent.

The definition of remission for JIA

An additional definition available for JIA is the CARRA/PRINTO/PRCSG criteria for inactive disease [48] that requires the absence of active arthritis, fever, rash, serositis, splenomegaly, or generalized lymphadenopathy attributable to JIA, active uveitis; normal ESR or CRP; and a physician’s global assessment of disease activity rated at the best score possible for the instrument used. The presence 6 continuous months of inactive disease defines clinical remission on medication, while 12 months of inactive disease off all anti-arthritis medications defines clinical remission off medication.

Final remarks and future perspective

The criteria for the evaluation of response to therapy in PRD were designed to ensure that certain minimum criteria/standards are applied to observational and randomized controlled trials and to facilitate comparison with future meta-analysis. Furthermore, they can assist in standardizing outcome measurements in daily clinical practice. The core set includes the indication of instruments that can be used to assess each domain. However the specific instrument can be modified or integrated whenever new valid tools or better laboratory indicators will be developed to measure a particular domain or more suitable for use in the paediatric age. The proposed core sets also combine aspects of the disease that can be measured easily in clinical practice and indeed only measures that can be assessed reliably world-wide were included.

In conclusion the proposed core sets and definitions of improvement incorporate clinically meaningful change in a composite endpoint for the evaluation of global response to therapy in the major PRD. The definitions are proposed for use in PRD clinical trials, and may help physicians to decide if a child has responded adequately to therapy.

ACKNOWLEDGMENTS.

"This contribution is part of the Task-force in Europe for Drug Development for the Young (TEDDY) Network of Excellence supported by the European Commission's Sixth Framework Program (Contract n. 0005216 LSHBCT- 2005-005126)"

We are indebted to PRINTO national coordinators and to the members of the PRINTO and of the PRCSSG networks, whose enthusiastic participation made these projects possible. The project has been supported by grant from the European Union (contract no. BMH4983531-CA, no. QLG1-CT-2000-00514), by IRCCS G. Gaslini, Genoa, Italy, and by the National Institute of Health (Grant RO3 AI 44046). Dr Dinara Guseinova, is a recipient of a EULAR scholarship.

Response to therapy in pediatric rheumatology. Part of TEDDY Supplement

Ruperto et al

Table 1: Core sets of measure to evaluate response to therapy in JIA, JSLE and JDM. In the first column are reported the overall domain. In the following columns the suggested variables to measure each specific domain in the 3 diseases.

DOMAINS*	Juvenile idiopathic arthritis (JIA)	Juvenile systemic lupus erythematosus (JSLE)	Juvenile dermatomyositis (JDM)
COMMON DOMAINS			
Global assessment by physicians	1) Physician's global assessment of disease activity on a 10-cm Visual analogue scale (VAS) or a 21 circle VAS	1) Physician's global assessment of disease activity on a 10-cm VAS or a 21 circle VAS	1) Physician's global assessment of disease activity on a 10-cm VAS or a 21 circle VAS
Global assessment by parents/patients	2) Patient/parent's assessment of overall well-being or a 10-cm VAS or a 21 circle VAS	2) Patient/parent's assessment of overall well-being or a 10-cm VAS or a 21 circle VAS	2) Patient/parent's assessment of overall well-being or a 10-cm VAS or a 21 circle VAS
Disability or Health Related Quality of Life	3) Childhood Health Assessment Questionnaire (CHAQ) or the Juvenile Arthritis Functionality Scale (JAFS)	3) Physical Summary score (PhS) of the Child Health Questionnaire (CHQ) or the Pediatric Rheumatology Quality of Life Scale (PRQL)	3) CHAQ or JAFS 4) CHQ-PhS or PRQL
DISEASE SPECIFIC DOMAINS			
Disease specific measures	4) Number of active joints 5) Number of joints with limited range of motion		5) Childhood Myositis Assessment Scale (CMAS) or Manual Muscle Testing (MMT)
Global disease activity		4) European Consensus Lupus Activity Measurement (ECLAM) or the Systemic Lupus Activity Measures (SLAM) or the SLEDAI	6) Disease Activity Score (DAS) or Myositis Disease Activity Assessment (MDAA)
Laboratory assessment	6) Erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP)	5) 24-hour proteinuria	
Additional	7) Spiking fever (to be used just for systemic JIA)		

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

For Peer Review

Table 2: Definitions to evaluate response to therapy in JIA, JSLE and JDM.

Juvenile idiopathic arthritis (JIA)	Juvenile systemic lupus erythematosus (JSLE)	Juvenile dermatomyositis (JDM)
Definition of improvement		
At least 30% (*) improvement from baseline in 3 of any 6 variables in the core set	At least 50% (*) improvement from baseline in any 2 among the 5 core set measures	At least 20% (*) improvement from baseline in 3 of any 6 core set domains
with no more than one of the remaining variables worsening by more than 30%.	with no more than 1 of the remaining worsening by more than 30%.	with no more than 1 of the remaining worsening by more than 30%, which cannot be muscle strength
For systemic JIA absence of spiking fever (< 2 days of maximal body temperature \leq 38°C during the week preceding the evaluation) is also required		
Definition of flare		
at least a 30% worsening in 3 of the 6 JIA core set parameters, with no more than one improving by more than 30%. (**)		

(*) report as secondary outcome also 50%-70%-90%-100% improvement

(**) Contingencies for JIA flare definition: if either the number of active joints or the number of joints with limitation of motion are used in the flare definition, there must be at least a two joint increase, respectively. Also, if the physical or parent global scales are used in the flare definition, worsening \geq 2 cm (on a 0-10 cm scale) is required. Additionally, for systemic JIA patients only, reappearance of spiking fever ($>$ 38°C, lasting for at least 2 days in the week preceding the evaluation) not due to infections would signify that a flare have occurred.

REFERENCES

- (1) Food and Drug Administration (FDA). Regulations requiring manufacturers to assess the safety and effectiveness of new drugs and biologic products in pediatrics patients (21 CFR Parts 201, 312, 314, and 601). *Federal Register* 1998;**63**(231).
- (2) Regulation (EC) no 1901/2006 of the European parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004. *Official Journal of the European Union* 2006;**L 378**:1-19.
- (3) Connor JD. A look at the future of pediatric therapeutics: an investigator's perspective of the new pediatric rule. *Pediatrics* 1999;**104**(3):610-3.
- (4) Ruperto N, Martini A, for the Paediatric Rheumatology International Trials Organization (PRINTO). Use of unlabelled and off licence drugs in children. A European paediatric rule is needed to protect children. *BMJ* 2000;**320**(7243):1210-1.
- (5) Ruperto N, Martini A. International research networks in pediatric rheumatology: the PRINTO perspective. *Curr Opin Rheumatol* 2004;**16**(5):566-70.
- (6) Ruperto N, Meiorin S, Iusan SM, et al. Consensus procedures and their role in pediatric rheumatology. *Curr Rheumatol Rep* 2008;**10**(2):142-6.
- (7) Delbecq AL, Van de Ven AH, Gustafson DH. Group Techniques for Program Planning. A guide to nominal group and Delphi processes. 1975;**1**.
- (8) Sniderman AD. Clinical trials, consensus conferences, and clinical practice. *Lancet* 1999;**354**(9175):327-30.
- (9) Giannini EH, Ruperto N, Ravelli A, et al. Preliminary definition of improvement in juvenile arthritis. *Arthritis Rheum* 1997;**40**(7):1202-9.
- (10) Ruperto N, Ravelli A, Falcini F, et al. Performance of the preliminary definition of improvement in juvenile chronic arthritis patients treated with methotrexate. *Ann Rheum Dis* 1998;**57**(1):38-41.

- 1
2
3 (11) Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology preliminary definition of
4 improvement in rheumatoid arthritis. *Arthritis Rheum* 1995;**38**:727-35.
- 5
6
7 (12) Strand V, Gladman D, Isenberg D, et al. Outcome measures to be used in clinical trials in systemic lupus
8 erythematosus. *J Rheumatol* 1999;**26**(2):490-7.
- 9
10
11 (13) Smolen JS, Strand V, Cardiel M, et al. Randomized clinical trials and longitudinal observational studies in
12 systemic lupus erythematosus: Consensus on a preliminary core set of outcome domains. *J Rheumatol*
13 1999;**26**(2):504-7.
- 14
15
16 (14) Rider LG, Giannini EH, Harris-Love M, et al. Defining Clinical Improvement in Adult and Juvenile Myositis.
17 *J Rheumatol* 2003;**30**(3):603-17.
- 18
19
20 (15) Rider LG, Giannini EH, Brunner HI, et al. International consensus on preliminary definitions of improvement
21 in adult and juvenile myositis. *Arthritis Rheum* 2004;**50**(7):2281-90.
- 22
23
24 (16) Oddis CV, Rider LG, Reed AM, et al. International consensus guidelines for trials of therapies in the idiopathic
25 inflammatory myopathies. *Arthritis Rheum* 2005;**52**(9):2607-15.
- 26
27
28 (17) Ruperto N, Ravelli A, Murray KJ, et al. Preliminary core sets of measures for disease activity and damage
29 assessment in juvenile systemic lupus erythematosus and juvenile dermatomyositis. *Rheumatology (Oxford)*
30 2003;**42**(12):1452-9.
- 31
32
33 (18) Ruperto N, Ravelli A, Cuttica R, et al. The Pediatric Rheumatology International Trials Organization criteria
34 for the evaluation of response to therapy in juvenile systemic lupus erythematosus: Prospective validation of
35 the disease activity core set. *Arthritis Rheum* 2005;**52**(9):2854-64.
- 36
37
38 (19) Ruperto N, Ravelli A, Oliveira S, et al. The Pediatric Rheumatology International Trials
39 Organization/American College of Rheumatology provisional criteria for the evaluation of response to therapy
40 in juvenile systemic lupus erythematosus. Prospective validation of the definition of improvement. *Arthritis*
41 *Rheum* 2006;**55**(3):355-63.
- 42
43
44 (20) Ruperto N, Ravelli A, Pistorio A, et al. The provisional Pediatric Rheumatology International Trial
45 Organization/American College of Rheumatology/European League Against Rheumatism disease activity core
46 set for the evaluation of response to therapy in juvenile dermatomyositis: a prospective validation study.
47 *Arthritis Rheum* 2008;**59**(1):4-13.
- 48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 (21) Boers M, Brooks P, Strand CV, Tugwell P. The OMERACT filter for Outcome Measures in Rheumatology. *J*
4 *Rheumatol* 1998;**25**(2):198-9.
5
6
7 (22) Bellamy N. Clinimetric concepts in outcome assessment: The OMERACT filter. *J Rheumatol* 1999;**26**(4):948-
8 50.
9
10
11 (23) Liang MH, Fossel AH, Larson MG. Comparisons of five health status instruments for orthopedic evaluation.
12 *Med Care* 1990;**28**(7):632-42.
13
14
15 (24) Cronbach LJ. Coefficient alfa and the internal structure of tests. *Psychometrika* 1951;**16**:297-334.
16
17
18 (25) Filocamo G, Davì S, Pistorio A, et al. Comparison of 21-numbered circle and 10-centimeter horizontal line
19 visual analog scales for physician's and parent's subjective ratings in juvenile idiopathic arthritis. *J Rheumatol*
20 2010;**in press**.
21
22
23 (26) Singh G, Athreya BH, Fries JF, Goldsmith DP. Measurement of health status in children with juvenile
24 rheumatoid arthritis. *Arthritis Rheum* 1994;**37**:1761-9.
25
26
27 (27) Guest Editors, Martini A, Ruperto N, for the Paediatric Rheumatology International Trials Organization
28 (PRINTO). Quality of life in juvenile idiopathic arthritis patients compared to healthy children. *Clin Exp*
29 *Rheumatol* 2001;**19** (suppl. 23):S1-S172.
30
31
32 (28) Ruperto N, Ravelli A, Pistorio A, et al. Cross-cultural adaptation and psychometric evaluation of the
33 Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ) in 32
34 countries. Review of the general methodology. *Clin Exp Rheumatol* 2001;**19**(4):S1-S9.
35
36
37 (29) Filocamo G, Sztajn bok F, Cespedes-Cruz A, et al. Development and validation of a new short and simple
38 measure of physical function for juvenile idiopathic arthritis. *Arthritis Rheum* 2007;**57**(6):913-20.
39
40
41 (30) Landgraf JM, Abetz L, Ware JE. The CHQ User's Manual. 1996;**First Edition**.
42
43
44 (31) Filocamo G, Schiappapietra B, Bertamino M, et al. A new short and simple health-related quality of life
45 measure for paediatric rheumatic diseases: initial validation in juvenile idiopathic arthritis. *Rheumatology*
46 2010;**in press**.
47
48
49 (32) Cassidy JT, Levinson JE, Bass JC, et al. A study of classification criteria for a diagnosis of juvenile
50 rheumatoid arthritis. *Arthritis Rheum* 1986;**29**:274-81.
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- (33) Ruperto N, Giannini EH. Redundancy of conventional articular response variables used in juvenile chronic arthritis clinical trials. *Ann Rheum Dis* 1996;**55**:73-5.
- (34) Ravelli A, Viola S, Ruperto N, et al. Correlation between conventional disease activity measures in juvenile chronic arthritis. *Ann Rheum Dis* 1997;**56**(3):197-200.
- (35) Bazso A, Consolaro A, Ruperto N, et al. Development and testing of reduced joint counts in juvenile idiopathic arthritis. *J Rheumatol* 2009;**36**(1):183-90.
- (36) Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. *Arthritis Rheum* 1992;**35**(6):630-40.
- (37) Liang MH, Socher SA, Larson MG, Schur PH. Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. *Arthritis Rheum* 1989;**32**:1107-18.
- (38) Vitali C, Bencivelli W, Isenberg DA, et al. Disease activity in systemic lupus erythematosus: report of the Consensus Study Group of the European Workshop for Rheumatology Research. II. Identification of the variables indicative of disease activity and their use in the development of an activity score. *Clin Exp Rheumatol* 1992;**10**:541-7.
- (39) Vitali C, Bencivelli W, Mosca M, et al. Development of a clinical chart to compute different disease activity indices for systemic lupus erythematosus. *J Rheumatol* 1999;**26**(2):498-501.
- (40) Lovell DJ, Lindsley CB, Rennebohm RM, et al. Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies - II. The Childhood Myositis Assessment Scale (CMAS): a quantitative tool for the evaluation of muscle function. *Arthritis Rheum* 1999;**42**(10):2213-9.
- (41) Rennebohm RM, Jones K, Huber AM, et al. Normal scores for nine maneuvers of the childhood myositis assessment scale. *Arthritis Rheum Arthritis Care Res* 2004;**51**(3):365-70.
- (42) Huber AM, Feldman BM, Rennebohm RM, et al. Validation and clinical significance of the childhood myositis assessment scale for assessment of muscle function in the juvenile idiopathic inflammatory myopathies. *Arthritis Rheum* 2004;**50**(5):1595-603.
- (43) Hicks J, Wesley R, Koziol D, et al. Validation of manual muscle testing (MMT) in the assessment of juvenile dermatomyositis (JDM). *Arthritis Rheum* 2000;**43**(Suppl):S194.

- 1
2
3 (44) Bode RK, Klein-Gitelman MS, Miller ML, Lechman TS, Pachman LM. Disease activity score for children
4 with juvenile dermatomyositis: Reliability and validity evidence. *Arthritis Rheum Arthritis Care Res*
5 2003;**49**(1):7-15.
6
7
8
9 (45) Isenberg DA, Allen E, Farewell V, et al. International consensus outcome measures for patients with idiopathic
10 inflammatory myopathies. Development and initial validation of myositis activity and damage indices in
11 patients with adult onset disease. *Rheumatology* 2004;**43**(1):49-54.
12
13
14 (46) Giannini EH, Lovell DJ, Silverman ED, et al. Intravenous immunoglobulin in the treatment of polyarticular
15 juvenile rheumatoid arthritis: a phase I/II study. *J Rheumatol* 1996;**23**(5):919-24.
16
17
18 (47) Brunner HI, Lovell DJ, Finck BK, Giannini EH. Preliminary definition of disease flare in juvenile rheumatoid
19 arthritis. *J Rheumatol* 2002;**29**(5):1058-64.
20
21
22
23 (48) Wallace CA, Ruperto N, Giannini E, et al. Preliminary criteria for clinical remission for select categories of
24 juvenile idiopathic arthritis. *J Rheumatol* 2004;**31**(11):2290-4.
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60